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Deﬁciency of apoprotein A-V (apoA-V) can cause hypertriglyceridemia. In an 11 months old boy pre-
senting with a severe hypertriglyceridemia, a formerly unknown 24 nucleotide deletion in exon 2 of the
APOA5 gene was detected. The homozygous mutation results in an eight amino acid loss in the signal
peptide sequence (c.16_39del; p.Ala6_Ala13del). Screening of control persons proved that this deletion is
a rare mutation. Hypertriglyceridemia in the patient was only found at the time when he was breast fed,
while after weaning, triglyceride levels were close to normal. Under both dietary conditions, apoA-V
protein was undetectable in plasma while post-heparin plasma lipoprotein lipase activity was normal.
Expression analysis of normal and mutated protein by Western blot and immunoﬂuorescence in apoA-
V deﬁcient primary hepatocytes revealed that, due to changes in the signal peptide, mutated apoA-V was
intracellularly missorted to lipid droplets and not secreted. Wild type apoA-V, instead, was not targeted
to lipid droplets but transported via endosomal compartments to the plasma membrane for secretion.
It is concluded that the c.16_39del mutation in the APOA5 gene leads to hepatic missorting and
impaired secretion, which consequently results in undetectable apoA-V plasma levels. The absence of
apoA-V in plasma leads under conditions of fat-rich diets to severe chylomicronemia, suggestive for a
modulatory role of apoA-V for lipoprotein lipase mediated intravascular triglyceride lipolysis.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Type 1 chylomicronemia is characterized by fasting plasma
triglyceride (TG) concentrations above 850 mg/dl (10 mmol/l).5, human apoA-V gene; DSP-
APOC2, human apoC-II gene;
GPI-anchored HDL-binding
T, wild type.
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r Ltd. Open access under CC BY-NC-NDThe onset of this disorder is usually during childhood; the most
common clinical presentation is recurrent acute pancreatitis.
Typically, this condition is caused by mutations in the lipoprotein
lipase gene (LPL) resulting in a deﬁcient hydrolysis of TG from
chylomicrons and VLDL. Less commonly, variants in the genes of
apoprotein C-II (APOC2, an essential LPL cofactor), apoprotein A-V
(APOA5, functions see below), GPI-anchored HDL-binding protein 1
(GPIHBP1, binding and transporting LPL to the endothelial surface)
or the lipase maturation factor 1 (LMF1, a factor involved in matu-
ration and translocation of lipases as LPL) can cause this phenotype.
A recent study revealed themajority of severe hypertriglyceridemia
type 1 cases being contributed to LPL defects (51%), about one third
being without detectable rare variants or with common variants,
and only about one sixth being caused by mutations in APOC2,
APOA5 or GP1HBP1. In type 5 hypertriglyceridemia, in most cases
common (77%) or no genetic variants were found [1].
Identiﬁed in 2001, apoA-V is one of the key players in plasma TG
metabolism. Since its discovery, different hypotheses explaining license.
Table 1
Plasma lipid and apoA-V concentrations in the patient, in his parents, an apoC-II
deﬁcient subject and in age-matched healthy controls.
Triglycerides
[mg/dl]
Cholesterol
[mg/dl]
HDL
cholesterol
[mg/dl]
apoA-V
[ng/ml]
Patient, breast-fed 2230 223 26 n.d.
Patient, after weaning 201 118 29 n.d.
Father 325 178 39 397
Mother 103 195 62 300
ApoC-II deﬁcient
control
2252 219 32 2534
Healthy controlsa 151  100 169  50 38  20 1113  537
n.d., not detectable.
a Means of 10 healthy children between 0 and 3 years.
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endothelial bound LPL and thereby decreases plasma TG concen-
tration [2,3]. Interactions with GPIHBP1 may be involved in this
process [4]. Second, apoA-V may act as a ligand to hepatocellular
receptors or proteoglycans [5,6]. Third, based on its structure, a role
of apoA-V in hepatocellular lipid secretion has been discussed [7].
Recent data suggested in addition, that apoA-V may guide TG to-
wards lipid droplet formation thereby decreasing hepatic VLDL
production [8].
Withmore than 40 single nucleotide polymorphisms (SNPs) and
other variations being reported, the human APOA5 gene is relatively
polymorphic. However, for most sequence aberrations, there are no
robust data regarding their functional relevance. Three widespread
haplotypes have been described to result in signiﬁcant differences
in human plasma TG levels, with APOA5*1 (most common variants
at all positions); APOA5*2 (rare alleles: 1131T>C, c.3A>G,
IVS3þ476G>T, c.1259T>C) and APOA5*3 (S19W; c.56C>G; signal
peptide variant) [9]. In genome wide association studies (GWAS),
APOA5 was found repeatedly to be one of the most signiﬁcant gene
loci inﬂuencing TG levels [10]. Beyond TG levels, APOA5 SNPs were
associatedwith cardiovascular disease, metabolic syndrome as well
as the response to a weight loosing diet and lipid medication [5,11].
To date, only few alterations in the APOA5 gene have been found
that cause type 1 or type 5 hypertriglyceridemia (Fig. 1). Three
nonsense mutations, p.Gln97X (c.289C>T) [12], p.Gln139X (c.415
C>T) [13], and p.Gln148X (c.442C>T) [14] result in a protein
truncation, and another three, c.49þ1G>A [15], c.161þ3G>C [16],
and c.161þ5G>C [17] cause aberrant splicing. Moreover,
sequencing of the APOA5 gene in severely hypertriglyceridemic
patients has revealed additional, so far unclassiﬁed missense vari-
ants, p.Glu255Gly (c.764A>G), p.Gly271Cys (c.821G>T),
p.His321Leu (c.962A>T) [18], p.Gly185Cys (c.553G>T) [19] and
p.Thr133Arg (c.398C>G) [1]. However, additional genetic or envi-
ronmental conditions are usually necessary to express the full
hypertriglyceridemic phenotype [20].
Here, we report a deletion of eight amino acids in the apoA-V
signal peptide which results in an intracellular protein missorting
and a hepatic apoA-V secretion defect. Clinically, the mutation
caused severe hypertriglyceridemia in an 11 months old boy at a
time when he was exclusively breast-fed. Remarkably, after
weaning on a normal diet the boy had almost normal plasma TG
concentrations.
2. Case report
A Turkish boy 11 months of age presented in an outlying chil-
dren’s hospital with intermittent abdominal pain. He was fully
breast fed without any restriction regarding frequency and time of
meals. Episodes of abdominal discomfort were not related to theAPOA5 gene
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Fig. 1. Structural mutations of the APOA5 gene. The newly discovered mutation is marked w
boxes, mature protein; I1eI3; introns, E1-E4: exons. See text for references.feeding status, they were explained by a mild pancreatitis with
repeatedly elevated plasma lipase activity up to 231 U/l (normal
<60 U/l) in the past. During blood drawing, a lipemic serum was
found. No medication had been taken recently.
2.1. Past medical history
The pregnancy was uncomplicated. The boy was born at term by
Caesarean section, with a normal length and weight of 52 cm and
3.4 kg, respectively. Besides recurrent bronchitis and a norovirus
infection, his medical history was unremarkable.
2.2. Family history
The parents were ﬁrst degree cousins, with their mothers being
siblings. The paternal grandfather had a cardiac infarction at age
45; his plasma TG concentration was found to be slightly elevated
(284 mg/dl; 3.35 mmol/l). The maternal grandfather suffered from
an early cardiac infarction at age 51; his plasma TG concentration
was 481 mg/dl (5.7 mmol/l) (Table 1). Except for the parents, none
of the family members was available for further analyses since they
are living in a rural area in Turkey.
2.3. Physical examination
On presentation, the patient’s length was 80 cm (90th percen-
tile) and his weight was 11.1 kg (75th percentile). Physical exami-
nation of lungs and heart was normal. The liver was palpable 1.5 cm
below costal margin; the spleenwas not palpable. No lipoid corneal
arc, xanthomata, or xanthelasma were found. Psychomotor skills
were appropriate for age. An abdominal ultrasound revealed a
slightly enhanced echo texture of liver and spleen. At that time, the
pancreas did not show any abnormal ﬁndings.3’3‘UTR
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ith a red box. White boxes, untranslated regions (UTR); gray boxes, signal peptide; black
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Routine laboratory values (blood count, GOT, GPT, creatinine,
clotting factors) were normal.When investigated by us, also plasma
pancreatic lipase activity was within normal limits. In addition,
normal values were found for vitamin A, E, D and essential fatty
acids in plasma phosphor lipids. Plasma lipoprotein concentrations
are shown in Table 1.
2.5. Ethical consideration
The parents agreed and gavewritten consent to genetic analyses
and biochemical work-up as well as a scientiﬁc publication. They
refused to have a liver biopsy performed in the boy. Work-up was
done in accordance with the Helsinki Declaration and the rules of
the Local Ethics Committee of the Hamburg Medical Association.
2.6. Follow-up
Upon our recommendation, the parents stopped breast feeding
and started to a regular formula-based diet. Only 4 weeks later, his
plasma TG concentration had decreased to an almost normal level
(Table 1) and episodes of abdominal pain were no longer present.
3. Methods
3.1. Genetic characterization
Direct sequencing of all exons, the intron/exon regions and the
ﬂanking untranslated sequences of APOA5, APOC3, LPL, and APOC2
was performed by standard techniques using the Sanger method on
an ABI/Hitachi 3500 Genetic Analyser. Results were automatically
compared by SeqPilot software version 4.0.1 to the respective
reference sequences (APOA5: NM_052968).
3.2. Genetic screening for heterozygote frequency
Using speciﬁc primers for APOA5 exon 2 (sn 50-TAA-
CAGGATTTCGGGCAGTT-30 and asn 50-TCTGCTGCCTCAACCTCTGT-
30), the wild type (WT) sequence renders a PCR product of 484 bp;
in the case of the detected mutation the shortened product has a
size of 460 bp. This difference was easily visualized on a 6% poly-
acrylamide gel (Supplemental Fig. 1). Furthermore, heterozygosity
for the deletion resulted in heteroduplex formation.
In order to investigate the frequency of the identiﬁed mutation
in the APOA5 gene, an anonymous gene bank from 50 healthy in-
dividuals of Turkish background living in Germany [21] was
screened for the mutation with this technique. Donors had agreed
to anonymous use of their DNA for future scientiﬁc use. DNA
samples were investigated with and without the admixture of WT
PCR products.
3.3. Plasma analysis
Plasma triacylglycerol and cholesterol measurements as well as
lipoprotein separation by sequential ultracentrifugation were per-
formed as described [2]. Lipoprotein proﬁling was done by FPLC
using an S6-superose column (GE Healthcare), and lipid levels were
analyzed in each fraction [2]. Total apoA-V plasma levels were
measured by a simple ELISA technique based on a rabbit polyclonal
antisera against the human apoA-V C-terminus [2]. His-tagged
apoA-V was puriﬁed by Ni-NTA column chromatography (Qiagen)
and subsequent size exclusion chromatography using a S200-
superose column (GE Healthcare). Recombinant apoA-V was used
as standard. Dilutions of standards and plasma samples wereimmobilized on Maxisorp microtiter plates (Nunc) and apoA-V
protein content was determined using apoA-V rabbit antisera and
ELISA Development Reagents (R&D Systems). The apoA-V concen-
tration of plasma samples was calculated in relation to the standard
curve (Supplemental Fig. 2). Plasma LPL activity was determined
using pre- and post-heparin plasma using an artiﬁcial glycerol tri-
[1-14C]oleate-containing lipid emulsion [22].
3.4. Animals
Animal experiments were done in accordance with the guide-
lines of the Federation of American Societies for Experimental
Biology and approved by the Department of Veterinary Affairs of
the State of Hamburg and the Animal Care Committee of the Uni-
versity Medical Center Hamburg-Eppendorf. FVB-background
apoA-V-deﬁcient (ApoA5/) mice [23] were used and genotyping
was performed as described [11].
3.5. Constructing plasmids
Plasmid DNA was ampliﬁed and isolated using XL1-blue E. coli
bacteria; ligated constructs were ampliﬁed by ultra-competent XL-
10-gold E. coli (Stratagene). WT-APOA5-containing pET-20b
plasmid kindly provided by Dr. R. O. Ryan (Oakland, CA) [24] was
restricted with NotI/XbaI FastDigest enzymes (Fermentas) and the
APOA5-wild-type sequence was cloned via NotI/XbaI restriction
enzyme sites into an Addgene pcDNA3.1-vector backbone for
expression. Plasmids were isolated using NucleoSpin Plasmid Kit
(MachereyeNagel). Gel extraction was performed using the
NucleoSpin Extract II Kit (MachereyeNagel). Primers for the site-
directed mutagenesis to produce c.16_39delAPOA5 were pur-
chased fromMWG. Sequence was checked via GATC Biotech Sanger
Service.
3.6. Cell culture
Primary hepatocytes were prepared according to Meredith [25]
with modiﬁcations as described [26]. Brieﬂy, harvested cells were
seeded in DMEM (10% FCS, 4.5 g/l glucose, [þ]gultamine, []py-
ruvate, 2% AntimycoticeAntibiotic from Invitrogen) medium to a
density of 200,000 cells/ml. Cells were transfected with WT or
mutant pcDNA-apoA-V or, for transfection control, with pcDNA-
EGFP with Lipofectamin2000 (Invitrogen). To induce the forma-
tion of lipid droplets, 36 h after transfection the cells were
administrated with oleic acid (incubated at 37 at 1200 rpm for 1 h
in DMEM þ 1 g/ml BSAþ BODIPY) to a concentration of 100 mM for
4 h and then harvested forWestern blotting or ﬁxedwith 4% PFA for
immunoﬂuorescence studies.
3.7. Western blotting
Primary hepatocyte supernatant and cell lysates were analyzed
via SDS-PAGE (GE Healthcare), electrotransferred on nitrocellulose
membrane (Whatman) and then probed with the following anti-
bodies: Rabbit polyclonal antisera against the human apoA-V C-
terminus 1:2.500 [2], apoE (Acris, 1:1000, rabbit), GAPDH (Novus
Biologicals, 1:1000, goat).
3.8. Immunoﬂuorescence studies
Fixed primary hepatocytes were washed with PBS and per-
meabilized with PGS (PBS þ 0.5 mg/ml saponin þ5 mg/ml glycine).
After blocking with Blocking Buffer I (AppliChem) cells were
incubated with following antibodies: apoA-V rabbit polyclonal
antiserum (1:250 rabbit, gift of Gunilla Olivecrona, Umeå, Sweden)
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tories). To visualize lipid droplets, BODIPY (Invitrogen) was used.
Nuclei were stained with DAPI.4. Results
4.1. Genetic characterization of the patient
Direct sequencing of all exons, the intron/exon regions and the
ﬂanking untranslated sequences of the LPL and the APOC2 genes did
not show any mutations. Analysis of the APOA5 gene revealed ho-
mozygosity for a deletion of 24 bases (c.16_39del) in the second
exon, predicting the loss of eight amino acids (p.Ala6_Ala13del)
within the apoA-V signal peptide (DSP-apoA-V) without frame
shift. Both parents were shown to be heterozygous carriers of this
gene defect (Fig. 2A and Supplemental Fig. 1). This eight amino acid
deletion in the signal peptide of apoA-V causes a difference in
maximal uninterrupted hydrophobic amino acids from 6 to 4 in a
row (Fig. 2B). Other frequently identiﬁed SNPs in the APOA5 gene
(haplotype APOA5*2 [1131T>C, c.3A>G, IVS3þ476G>A,
c.1259T>C], haplotype APOA5*3 [c.56C>G; p.S19W], and the poly-
morphism c.553G>T, p.G185C) were not found [9]. The situation in
the APOC3 gene, another TG inﬂuencing gene, was as follows:
482C>T (rs2854117), T/T; 455T>C (rs2854116), C/C and
3238C>G (Sst I site; rs5128), C/C. Taken together, except for the
disruption of the apoA-V signal peptide, no other mutation was
found which may have caused the phenotype of the patient.4.2. Mutation frequency
To investigate the frequency of the identiﬁed mutation of the
APOA5 gene in the general Turkish population, an anonymous gene
bank from 50 individuals with Turkish ancestors living in the region
around Munich, Germany, was screened using the method
described for supplemental Fig. 1. From one sample no PCR product
could be generated; none of the other analyzed APOA5 genes car-
ried the mutation. Thus, in 98 chromosomes c.16_39del was not
found, indicating that this mutation is not a common APOA5 variant
in the Turkish population. In addition, the 1000genomes and the
Exome Variant Server databases have been checked for genetic
variations in the APOA5 gene. The newly discovered mutation was
not reported in these two databases. Even more, no in frameFig. 2. Identiﬁcation of the APOA5 signal peptide deletion. A, sequencing of the APOA5 gen
(c.16_39del) is detected in the patient, and a heterozygous pattern was found in both parents
patient resulting in DSP-apoA-V. This causes a difference in maximal uninterrupted hydroph
the signal peptide.deletions in the coding sequence are described so far (http://www.
1000genomes.org; http://evs.gs.washington.edu/EVS/).4.3. Biochemical characterization of the patient
Plasma levels of apoA-V were measured by ELISA and compared
to the ApoA-V levels of the parents as well as to 10 age-matched
controls. As shown in Table 1, apoA-V was not found in the pa-
tient’s blood both in the hypertriglyceridemic state and after
weaning. Diminished apoA-V plasma concentrations were present
in both parents. Plasma pre- and post-heparin LPL activity was
normal in the patient. Addition of apoA-V did not change in vitro
LPL activity (Supplemental Table 1). To investigate TG hydrolysis
in vivo, plasma FPLC chromatography before and after heparin-
ization was performed (supplemental Fig. 3). In the apoA-V deﬁ-
cient patient, the VLDL/chylomicron peak decreased and a glycerol
peak appeared after heparin injection. Both effects are the results of
LPL-mediated TG hydrolysis in plasma. In contrast, in an apoC-II
deﬁcient patient [27], there were no changes in the TG peak, and
no glycerol peak arose. Since apoA-V accelerates TG hydrolysis
especially at endothelial bound LPL [2], this effect supports the
hypothesis, that a lack of plasma apoA-V caused the hyper-
triglyceridemia in the patient under high fat diet conditions.4.4. Expression analysis of WT and DSP-apoA-V
To investigate the secretion of WT and DSP-apoA-V from he-
patocytes, both proteins were expressed in primary hepatocytes
from apoA-V deﬁcient mice. First, medium and cell lysates were
investigated for apoA-V by Western blot. As shown in Fig. 3 (upper
panels), both after incubation with BSA and HDL as apoA-V
acceptor, the 38 kDa apoA-V band was almost only seen in the
WT situation. Only traces of apoA-V were detectable in the super-
natants of cells transfected with DSP-apoA-V. In contrast, the cell
lysates of DSP-apoA-V transfected cells contained signiﬁcantly
higher amounts of apoA-V than cells expressing WT-apoA-V (Fig. 3,
lower panels). No apoA-V signal was detected after GFP transfection
in these apoA-V deﬁcient hepatocytes.
Indirect immunoﬂuorescence using an antibody against apoA-V
and lipid droplet staining was performed to gain information about
the intracellular fate of mutated apoA-V. In Fig. 4 AeD, transfected
WT apoA-V (red) was clearly located at the plasma membranee in the patient, in his parents and in a control subject. A homozygous 24-bp-deletion
. B, eight amino acids (marked in red) are deleted in the signal peptide of apoA-V in the
obic amino acids in a row (lower panel) which is likely to result in a loss-of-function of
Fig. 3. Detection of apoA-V by Western blot in culture supernatant and cell lysates
after expression of different variants in primary hepatocytes from apoA-V deﬁcient
mice. GFP, control vector; WT-A-V, wild type apoA-V; DSP-A-V, DSP-apoA-V
(c.16_39del_apoA-V). The medium was supplemented with BSA or HDL as apoA-V
acceptor, respectively. Western blot was carried out using rabbit apoA-V antiserum.
K. Albers et al. / Atherosclerosis 233 (2014) 97e103 101distinct from green lipid droplets. However, the signal ofDSP-apoA-
V (Fig. 4 EeH) was not associated with the plasma membrane.
Instead, mutated apoA-V was completely co-localized with lipid
droplets (yellow in web version in Fig. 4 G and H). Thus, partial
deletion of the apoA-V signal peptide leads to intracellular mis-
sorting and defective secretion of the apoA-V protein.
5. Discussion
In a young boy with severe hypertriglyceridemia, a defective
plasmatic TG hydrolysis due to an eight amino acid deletion in
frame in the apoA-V signal peptide (APOA5 c.16_39del; DSP-apoA-V)Fig. 4. Deletion in the apoA-V signal peptide causes intracellular missorting of newly synth
encoding either wild type apoA-V (AeD) or apoA-V with a deleted signal peptide region (
labeled fatty acids to visualize lipid droplets (B, F), indirect immunoﬂuorescence using a
type apoA-V is localized at the plasma membrane (C), whereas DSP-apoA-V co-localizes w
respectively. Bars denote 20 mm.was found to cause this condition. To our knowledge, this mutation
has not been described before. At the positions of frequently
identiﬁed SNPs in the APOA5 gene, the most common haplotype
APOA5*1was found to be associatedwith the lowest TG levels [9]. In
the APOC3 gene, 482T/T and 455C/C have been associated with
mild TG increase, 3238C/C is associated with lower TG levels ac-
cording to different investigators [28,29]. In any case, neither
polymorphisms in the APOA5 nor in the APOC3 genes suggested
other genetic causes for hypertriglyceridemia.
Single homozygosity or compound heterozygosity for mutations
in the APOA5 gene are less common causes of severe hyper-
triglyceridemia [1]. About eleven mutations and about 20 patients
have been reported thus far. The mutation described here has not
been previously reported. In most cases, even severe structural
apoA-V changes were not sufﬁcient to cause hypertriglyceridemia
alone. Other factors such as age, additional APOA5 sequence aber-
rations (reported with APOA5 p.Gln97X [12,30], p.Gln139X [13],
p.Gln148X [14], p.Gly271Cys [18] and c.49þ1G>A [15]), LPL muta-
tions (reported with APOA5 p.Glu255Gly and APOA5 p.His321Leu
[18]), reduced LPL activity (APOA5 c.161þ3G>C [16]), or pregnancy
(APOA5 c.161þ5G>C [17] and APOA5 p.Glu255Gly 18) or HIV therapy
(APOA5 p.Gly185Cys [31]) were necessary to result in the full
hypertriglyceridemic phenotype.
With his age of only 11 months, our patient had the earliest
manifestation of a hypertriglyceridemia associated with an APOA5
mutation ever reported. However, as reported for other cases
described above, an additional factor was necessary for disease
manifestation: Severe hypertriglyceridemia and abdominal pain
were only found on a diet with a relatively high fat content at an
age when he was exclusively fed breast milk (supplying about 50%
of energy from fat). When a normal, mildly fat-reduced regular
toddler’s diet with a calculated caloric intake from fat of 35% was
fed, plasma TG concentration decreased substantially to almost
normal.
SNPs in the APOA5-gene have been found to be strongly asso-
ciated with plasma TG levels [32]. This is especially true
for 1131T>C, a polymorphism which in Caucasians is in strong
linkage disequilibrium with c.3A>G, IVS3þ476G>A and
c.1259T>C [9,33]. In a genome-wide linkage analysis for TG levels
in a subset of Turkish families originating both from Istanbul and aesized apoA-V. Primary apoA-V-deﬁcient hepatocytes were transfected with plasmids
c.16_39del_apoA-V; DSP-apoA-V; EeH). After incubation with oleic acids and Bodipy-
n antibody against apoA-V was performed (A, E). Merged images showed that wild
ith lipid droplets (G). Magniﬁed images of the dotted boxes are shown in D and H,
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was found at 11q22 [34]. This suggests that apoA-V may be of high
importance for TG regulation also in this population. Data from the
Turkish Heart Study (THS) have revealed an incomplete linkage
disequilibrium between 1131T>C, -1464T>C and c.1259T>C,
however, sequencing of the untranslated region (UTR) and all exons
intron/exon splicing boundaries auf APOA5 in participants of this
study did not reveal the deletion c.16_39del described here [35].
Despite this strong evidence, that the mutation found in this pa-
tient is not a common APOP5 polymorphism, we tested 49
randomly selected samples (98 chromosomes) from healthy in-
dividuals of Turkish background living in Germany for this muta-
tionwithout ﬁnding c.16_39del. Thus, the APOA5 promoter deletion
c.16_39del seems indeed to be a rare functionally signiﬁcant mu-
tation and not a polymorphism.
No apoA-V was detected in the patient’s plasma and reduced
apoA-V levels were found in his parents. It was therefore suggested,
that the signal peptide mutation disturbs intracellular trafﬁcking
and secretion. The deletion c.16_39del (p.Ala6_Ala13del,DSP-apoA-
V) affects the signaling sequence which consists of the 23 N-ter-
minal amino acids of the protein. The deletion causes a difference in
maximal uninterrupted hydrophobic amino acids in a row from six
(WT) to four (DSP-apoA-V). This is per se likely to result in a loss-of-
function of the signal peptide.
Several experiments were performed to ﬁnd out, whether and
how apoA-V secretion was affected by the signal peptide mutation.
Since a liver biopsy was clinically not justiﬁed, expression of WT
and mutated apoA-V was performed in primary hepatocytes from
apoA-V defective mice. Western blot analysis showed DSP-apoA-V
in high amounts almost exclusively intracellularly, whereas WT-
apoA-V was secreted from hepatocytes with less protein left over
intracellularly. In addition, as shown by immunoﬂuorescence,
partial deletion of the apoA-V signal peptide leads to intracellular
missorting to hepatocellular lipid droplets and defective secretion
of the protein. In contrast, WT-apoA-V was located mainly at the
plasma membrane. A localization of apoA-V at the plasma mem-
brane was theoretically predicted and proven by immunoﬂuores-
cence by Weinberg and co-workers [7]. Indirect immune
ﬂuorescence from livers of apoA-V transgenic mice also depicted a
clear localization of human apoA-V at the hepatocellular plasma
membrane (Supplemental Fig. 4).
It can be concluded that, under normal conditions, high
amounts of apoA-V are located at the hepatocellular plasma
membrane for secretion. Only due to missorting because of a
defective signal peptide, apoA-V is transported to lipid droplets.
These data are in contrast to the results of Shu and co-workers [36].
When expressing a FLAG-tagged full length apoA-V in the Hep3B
hepatoma cell line, the authors found the protein being associated
mainly with lipid droplets. A change in protein processing due to
the FLAG tag or the cell model used could be the reason for this
difference to our data using primary hepatocytes. In any case, a
possible inﬂuence of apoA-V on the formation of lipid droplets e
maybe due to increased lipid uptake by apoA-V as described by Gao
et al. [8] e could still occur, since apoA-V is signiﬁcantly upregu-
lated during liver regeneration [37]. Last but not least, altering
signal peptide cleavage could be a way to regulate the fate of liver
TG either to droplets or to VLDL formation.
The precise mechanism, how apoA-V decreases plasma TG
concentration, is not completely understood. In plasma, apoA-V is
mainly bound to VLDL and HDL at very low concentrations. It has
been demonstrated, that apoA-V can accelerate plasma TG catab-
olism by affecting proteoglycan bound LPL [2,3]. However, it could
also act as a ligand for hepatic lipoprotein receptors or pro-
teoglycans enhancing remnant removal [38]. In this patient,
detaching LPL from endothelial proteoglycans by heparin resultedin fast TG hydrolysis even in the apoA-V deﬁcient situation.
Without heparin, the lipoprotein proﬁle is equal to that of an apoC-
II deﬁcient subject with high TG and no glycerol peak. This clearly
shows that apoA-V is essential for the hydrolysis of plasma TG by
proteoglycan bound LPL, but not for the enzymatic action of un-
bound LPL.
Taken together, a novel structural mutation in the APOA5 gene
(c.16_39del_APOA5) with a deleterious effect on plasma TG hydro-
lysis was identiﬁed. This signal peptide mutation causes an intra-
cellular missorting and plasma deﬁciency of apoA-V leading to
severe hypertriglyceridemia on a diet relatively high in fat, but not
on a fat-reduced diet.
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